Consolidated Balance Sheets - USD ($) $ in Millions		Mar. 31, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents		$ 4,452	$ 4,619
Investments		973	937
Accounts receivable, net		11,735	10,716
Inventories		2,565	2,661
Other current assets		1,733	1,400
Assets of business held for sale		9,419	9,512
Total current assets		30,877	29,845
Long-term investments		20,608	21,542
Reinsurance recoverables		5,047	5,100
Deferred policy acquisition costs		2,959	2,958
Property and equipment		4,317	4,417
Goodwill		44,584	44,602
Other intangible assets		36,162	36,562
Other assets		2,517	2,283
Separate account assets		7,640	8,465
TOTAL ASSETS		154,711	155,774
Liabilities
Current insurance and contractholder liabilities		5,030	4,921
Pharmacy and service costs payable		10,797	10,454
Accounts payable		5,585	5,090
Accrued expenses and other liabilities		7,585	7,347
Short-term debt		4,340	5,514
Liabilities of business held for sale		7,043	6,812
Total current liabilities		40,380	40,138
Non-current insurance and contractholder liabilities		15,838	16,052
Deferred tax liabilities, net		9,066	9,387
Other non-current liabilities		4,519	4,460
Long-term debt		32,147	31,893
Separate account liabilities		7,640	8,465
TOTAL LIABILITIES		109,590	110,395
Contingencies — Note 19
Redeemable noncontrolling interests		35	35
Shareholders’ equity
Common stock	[1]	4	4
Additional paid-in capital		28,554	28,306
Accumulated other comprehensive loss		(1,527)	(941)
Retained earnings		21,298	20,162
Less: treasury stock, at cost		(3,250)	(2,193)
TOTAL SHAREHOLDERS’ EQUITY		45,079	45,338
Other noncontrolling interests		7	6
Total equity		45,086	45,344
Total liabilities and equity		$ 154,711	$ 155,774

[1] Par value per share, $0.01; shares issued, 388 million as of March 31, 2020 and 386 million as of December 31, 2019; authorized shares, 600 million.